Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC95468 tablets for pulmonary arterial hypertension
CTR20232659Phase 3Active
- Sponsor
- HEC Pharm
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HEC95468 in pulmonary arterial hypertension (PAH), sponsored by HEC Pharm. Started Sep 2023; status: active.
02
Drugs
HEC95468
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20232659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232659.